GlassScriptPhysician profile
John Samuel Barbara
NPI 1699395558
$2,175.69
in general payments reported to CMS, 2019-2025
24 companies · $869 in 2025
The $869 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.04 · 2022: $398 · 2023: $164 · 2024: $726 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $649.39 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $222.66 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $209.60 | 2022-2025 | Qelbree |
| Glaxosmithkline, LLC. | $199.13 | 2025 | Penmenvy, Bexsero, Menveo |
| Regeneron Healthcare Solutions, INC. | $165.34 | 2022-2024 | Dupixent |
| Corium, LLC | $117.98 | 2024-2025 | Azstarys |
| Novo Nordisk INC | $106.65 | 2022 | |
| Pfizer INC. | $96.26 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $83.71 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $58.31 | 2024-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Seqirus USA INC | $24.14 | 2025 | Flucelvax |
| Ars Pharmaceuticals Operations, INC. | $22.93 | 2025 | Neffy |
| Grifols USA, LLC | $22.89 | 2023 | Xembify |
| Sanofi Pasteur INC. | $22.21 | 2024 | |
| Cipher Pharmaceuticals US LLC | $22.01 | 2025 | Natroba, Spinosad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.52 | 2023 | Gvoke Hypopen |
| Phadia US INC. | $20.66 | 2024 | Immunocap |
| Csl Behring | $19.04 | 2021 | |
| Tris Pharma INC | $17.99 | 2025 | Onyda Xr |
| Viiv Healthcare Company | $17.81 | 2024 | Apretude |
| Cranial Technologies, INC | $15.18 | 2024 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $14.90 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2024 | Zoryve |
| Daiichi Sankyo INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.